europeanpharmaceuticalreviewMay 13, 2021
Tag: PAT , raman analyser , spectroscopy
According to a recent report, the real-time bioprocess Raman analyser market is expected to grow at a compound annual growth rate (CAGR) of 14.6 percent between 2021 and 2030. The primary drivers of this growth include rising investment in research towards cloud-based spectroscopy and the regulatory push to introduce process analytical technologies (PAT), with PAT enabled Raman analysers now available on the market.
Real-time bioprocess Raman analysers are devices that use Raman spectroscopy as a vibration or optical analysis technique to provide chemical and physical molecular fingerprints for a sample. According to the report, Raman spectroscopy enables a complete understanding of bioprocess and real-time control of nutrients and metabolites.
The investigators stated that initiatives by governments to encourage investment in pharma R&D and rising healthcare expenditure will both fuel demand for real-time bioprocess Raman analysers. Additionally, the US Food and Drug Administration (FDA) and other regulators promoting the use of PAT and PAT enabled Raman analysers for the manufacture of high-quality biopharmaceuticals and to increase the rate of production through automating data processing will also prompt growth.
Other factors propelling the expansion of the market include technological advancements and mergers and acquisitions undertaken by leading market players, which the report suggests resulted in 6.2 percent market growth between 2018 and 2019. For instance, Merck KGaA acquiring Resolution Spectra Systems Inc. in 2020 lead to market expansion for real-time bioprocess Raman analysers.
The report did caution however, that though developed nations have actively adopted real-time bioprocess Raman analysers, emerging nations are yet to do so, primarily because of a lack of information and high product costs. According to the investigators, these factors, in addition to COVID-19 resulting in the large-scale closure or disruption of manufacturing units, have majorly impacted the real-time bioprocess Raman analysers market.
In terms of geography, the US is expected to remain the most lucrative market for these technologies, anticipated to achieve a CAGR of 14 percent between 2021 and 2020. The growth in this market is driven by the large number of bioprocessing companies and contract manufacturing organisations (CMOs) in the region.
According to the report, though they identified a lack of awareness around real-time bioprocess Raman analysers in China, increasing healthcare expenditure in the country is expected to promote growth. With healthcare expenditure accounting for nearly six percent of GDP in the last decade, the investigators suggest it remains the second most attractive region for real-time bioprocess Raman analysers market growth, anticipated to grow at a CAGR of 18.9 percent during the forecast period as a result of the large number of CMOs in the region.
Japan is another country within the Asia Pacific (APAC) region that is expected to achieve significant growth, with a CAGR of >11 percent anticipated in the forecast period. While the report cautions that the country’s limited number of CMOs may restrain market growth, Japan’s increasing healthcare expenditure (10.95 percent of GDP in 2018) and rising focus on advanced healthcare technologies will support expansion. Additionally, the development of a strong contract development and manufacturing industry should drive growth in the real-time bioprocess Raman analysers market also.
India is also an attractive market, since its pharmaceutical industry is ranked third in terms of the volume of biopharmaceutical products manufactured. Additionally, India attracts investment as it has a high volume of CMOs and lower labour costs with high manufacturing capabilities. Additionally, the contribution of its GDP to healthcare is growing as the country works to develop a healthcare infrastructure. Hence, India with the increasing biopharmaceutical manufacturing and bioprocessing activities is expected to observe significant growth of the market dealing with real-time bioprocess Raman analysers.
The report states that the UK has emerged as the primary market for real-time bioprocess Raman analysers due to its growing GDP and expanding healthcare infrastructure. Additionally, the report states the availability of skilled labour and government initiative promoting the expansion of the UK’s pharmaceutical and biopharmaceutical sectors are also factors in the growth of the market.
By component, Raman analysers account for the largest share of the market and are anticipated to attain over 70 percent of the market during the forecast period. This is due to the rising demand for Raman spectroscopy solutions and data processing in real-time for PAT, as well as the focus on quality by design. Raman probes are also a major part of real-time bioprocess Raman analysers and hold the second position in terms of demand across all key regions.
Accounting for over 70 percent of the market, bioprocess analysis is forecasted to remain the dominant application during the forecast period.
Key market players include Kaiser Optical Systems (Endress+Hauser), Resolution Spectra Systems Inc. (Merck KGaA), Tornado Spectral Systems and Sartorius AG.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: